New drug combo aims to outsmart Chemo-Resistant ovarian cancer

NCT ID NCT04092270

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: peposertib (M3814) and pegylated liposomal doxorubicin (PLD)
What this could lead to: If it works, this could point toward a new treatment option for ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong: This is a very early (Phase I) trial with only 54 participants, so it is primarily testing safety and dosing. The combination may not prove effective or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL HIGH GRADE ENDOMETRIOID ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial endometrioid adenocarcinoma fallopian tube cancer fallopian tube carcinoma fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube mucinous adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma fallopian tube transitional cell carcinoma neoplasm ovarian cancer ovarian carcinoma ovarian carcinosarcoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma ovarian seromucinous carcinoma ovarian serous adenocarcinoma ovarian transitional cell carcinoma primary peritoneal carcinoma primary peritoneal serous adenocarcinoma primary peritoneal serous/papillary carcinoma undifferentiated ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL HIGH GRADE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE CARCINOSARCOMA FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA FALLOPIAN TUBE MALIGNANT MIXED MESODERMAL (MULLERIAN) TUMOR FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA FALLOPIAN TUBE TRANSITIONAL CELL CARCINOMA FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA FIGO GRADE 1 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN SEROMUCINOUS CARCINOMA OVARIAN UNDIFFERENTIATED CARCINOMA PLATINUM-SENSITIVE OVARIAN CARCINOMA PRIMARY PERITONEAL CARCINOSARCOMA PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT OVARIAN CARCINOSARCOMA RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA RECURRENT OVARIAN LOW GRADE SEROUS ADENOCARCINOMA RECURRENT OVARIAN MALIGNANT MIXED MESODERMAL (MULLERIAN) TUMOR RECURRENT OVARIAN MUCINOUS ADENOCARCINOMA RECURRENT OVARIAN TRANSITIONAL CELL CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA RECURRENT PRIMARY PERITONEAL LOW GRADE SEROUS ADENOCARCINOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.